M Hiligsmann1, O Bruyère, J-Y Reginster. 1. Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium. m.hiligsmann@ulg.ac.be
Abstract
UNLABELLED: The results of this study suggested that long-term treatment with strontium ranelate over 5 years is cost-effective compared to no treatment for postmenopausal osteoporotic women. INTRODUCTION: This study aims to estimate the cost-effectiveness of long-term strontium ranelate treatment for postmenopausal osteoporotic women. METHODS: A validated Markov microsimulation model with a Belgian healthcare cost perspective was used to assess the cost per quality-adjusted life-year (QALY) of strontium ranelate compared to no treatment, on a basis of calcium/vit D supplementation if needed. Analyses were performed for women aged 70, 75, and 80 years either with a bone mineral density T-score <or= -2.5 SD or with prevalent vertebral fractures. The relative risk of fracture during therapy was derived from the Treatment of Peripheral Osteoporosis Study trial over 5 years of treatment. Parameter uncertainty was evaluated using both univariate and probabilistic sensitivity analyses. RESULTS:Strontium ranelate was cost-saving at the age of 80 years in both populations. For women with a T-score <or= -2.5 SD, the costs per QALY gained of strontium ranelate were respectively euro 15,096 euro and 6,913 euro at 70 and 75 years of age while these values were 23,426 euro and 9,698 euro for women with prevalent vertebral fractures. Sensitivity analyses showed that the results were robust over a wide range of assumptions. CONCLUSION: This study suggested that, compared to no treatment, long-term strontium ranelate treatment is cost-effective for postmenopausal osteoporotic women.
RCT Entities:
UNLABELLED: The results of this study suggested that long-term treatment with strontium ranelate over 5 years is cost-effective compared to no treatment for postmenopausal osteoporoticwomen. INTRODUCTION: This study aims to estimate the cost-effectiveness of long-term strontium ranelate treatment for postmenopausal osteoporoticwomen. METHODS: A validated Markov microsimulation model with a Belgian healthcare cost perspective was used to assess the cost per quality-adjusted life-year (QALY) of strontium ranelate compared to no treatment, on a basis of calcium/vit D supplementation if needed. Analyses were performed for women aged 70, 75, and 80 years either with a bone mineral density T-score <or= -2.5 SD or with prevalent vertebral fractures. The relative risk of fracture during therapy was derived from the Treatment of Peripheral Osteoporosis Study trial over 5 years of treatment. Parameter uncertainty was evaluated using both univariate and probabilistic sensitivity analyses. RESULTS:Strontium ranelate was cost-saving at the age of 80 years in both populations. For women with a T-score <or= -2.5 SD, the costs per QALY gained of strontium ranelate were respectively euro 15,096 euro and 6,913 euro at 70 and 75 years of age while these values were 23,426 euro and 9,698 euro for women with prevalent vertebral fractures. Sensitivity analyses showed that the results were robust over a wide range of assumptions. CONCLUSION: This study suggested that, compared to no treatment, long-term strontium ranelate treatment is cost-effective for postmenopausal osteoporoticwomen.
Authors: Fredrik Borgström; Olof Johnell; John A Kanis; Anders Oden; David Sykes; Bengt Jönsson Journal: Pharmacoeconomics Date: 2004 Impact factor: 4.981
Authors: F Lekkerkerker; J A Kanis; N Alsayed; G Bouvenot; N Burlet; D Cahall; A Chines; P Delmas; R-L Dreiser; D Ethgen; N Hughes; J-M Kaufman; S Korte; G Kreutz; A Laslop; B Mitlak; V Rabenda; R Rizzoli; A Santora; R Schimmer; Y Tsouderos; P Viethel; J-Y Reginster Journal: Osteoporos Int Date: 2007-06-22 Impact factor: 4.507
Authors: Jean-Yves Reginster; Dieter Felsenberg; Steven Boonen; Adolfo Diez-Perez; Rene Rizzoli; Maria-Luisa Brandi; Tim D Spector; Kim Brixen; Stefan Goemaere; Catherine Cormier; Adam Balogh; Pierre D Delmas; Pierre J Meunier Journal: Arthritis Rheum Date: 2008-06
Authors: Mickaël Hiligsmann; Silvia M Evers; Wafa Ben Sedrine; John A Kanis; Bram Ramaekers; Jean-Yves Reginster; Stuart Silverman; Caroline E Wyers; Annelies Boonen Journal: Pharmacoeconomics Date: 2015-03 Impact factor: 4.981
Authors: J E M Sale; A Yang; V Elliot-Gibson; R Jain; R Sujic; D Linton; J Weldon; L Frankel; E Bogoch Journal: Osteoporos Int Date: 2021-01-20 Impact factor: 4.507
Authors: J-Y Reginster; M-L Brandi; J Cannata-Andía; C Cooper; B Cortet; J-M Feron; H Genant; S Palacios; J D Ringe; R Rizzoli Journal: Osteoporos Int Date: 2015-04-14 Impact factor: 4.507
Authors: Mickael Hiligsmann; John A Kanis; Juliet Compston; Cyrus Cooper; Bruno Flamion; Pierre Bergmann; Jean-Jacques Body; Steven Boonen; Olivier Bruyere; Jean-Pierre Devogelaer; Stefan Goemaere; Jean-Marc Kaufman; Serge Rozenberg; Jean-Yves Reginster Journal: Calcif Tissue Int Date: 2013-03-21 Impact factor: 4.333